Merck & Co. SG&A increased by 10.1% to $2.90B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 1.3%, from $2.86B to $2.90B. Over 4 years (FY 2021 to FY 2025), SG&A shows an upward trend with a 2.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Increases may indicate aggressive marketing or expansion, while decreases often reflect cost-cutting measures or improved corporate efficiency.
The sum of all direct and indirect selling expenses and all general and administrative expenses of a company. This inclu...
Used to assess the 'leaness' of a company's corporate structure relative to its peers.
is_selling_general_and_administrative| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.28B | $2.34B | $2.38B | $2.32B | $2.51B | $2.52B | $2.69B | $2.48B | $2.70B | $2.52B | $2.80B | $2.48B | $2.74B | $2.73B | $2.86B | $2.55B | $2.65B | $2.63B | $2.90B |
| QoQ Change | — | +2.4% | +2.1% | -2.6% | +8.1% | +0.3% | +6.6% | -7.7% | +9.0% | -6.8% | +11.3% | -11.4% | +10.3% | -0.3% | +4.8% | -10.9% | +3.8% | -0.6% | +10.1% |
| YoY Change | — | — | — | — | +10.1% | +7.9% | +12.7% | +6.7% | +7.6% | -0.0% | +4.4% | +0.2% | +1.4% | +8.4% | +2.1% | +2.8% | -3.3% | -3.6% | +1.3% |
We use cookies for analytics. See our Privacy and Cookie Policy.